Vera Therapeutics, Inc. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2026-04-09: Measure Advancing atacicept towards U.S. approval in IgAN.
- 2026-04-09: Measure Preparing for successful U.S. launch of atacicept in IgAN.
- 2026-04-09: Measure Advancing lifecycle management and broader portfolio.
| Proxy filed | Measure |
|---|---|
| 2026-04-09 | Advancing atacicept towards U.S. approval in IgAN |
| 2026-04-09 | Preparing for successful U.S. launch of atacicept in IgAN |
| 2026-04-09 | Advancing lifecycle management and broader portfolio |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |